Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA.

Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15.


GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.

Durham NM, Holoweckyj N, MacGill RS, McGlinchey K, Leow CC, Robbins SH.

J Immunother Cancer. 2017 Jun 20;5:47. doi: 10.1186/s40425-017-0247-0. eCollection 2017.


Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.

Durham NM, Mulgrew K, McGlinchey K, Monks NR, Ji H, Herbst R, Suzich J, Hammond SA, Kelly EJ.

Mol Ther. 2017 Aug 2;25(8):1917-1932. doi: 10.1016/j.ymthe.2017.05.006. Epub 2017 Jun 2.


Self-Generated Magnetic Fields in the Stagnation Phase of Indirect-Drive Implosions on the National Ignition Facility.

Walsh CA, Chittenden JP, McGlinchey K, Niasse NPL, Appelbe BD.

Phys Rev Lett. 2017 Apr 14;118(15):155001. doi: 10.1103/PhysRevLett.118.155001. Epub 2017 Apr 10.


Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.

Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, Fleming R, Bezabeh B, Meekin J, Stewart D, Kennedy M, Martin P, Buchanan A, Dimasi N, Michelotti E, Hollingsworth R.

Cancer Res. 2017 May 15;77(10):2686-2698. doi: 10.1158/0008-5472.CAN-16-2854. Epub 2017 Mar 10.


A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.

Leyland R, Watkins A, Mulgrew KA, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S, Oberst MD, Coates Ulrichsen J, Leinster DA, McGlinchey K, Young L, Morrow M, Hammond SA, Mallinder P, Herath A, Leow CC, Wilkinson RW, Stewart R.

Clin Cancer Res. 2017 Jul 1;23(13):3416-3427. doi: 10.1158/1078-0432.CCR-16-2000. Epub 2017 Jan 9.


Targeting CD73 in the tumor microenvironment with MEDI9447.

Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, Hammond SA, Rothstein R, Rios-Doria J, Poon E, Holoweckyj N, Durham NM, Leow CC, Diedrich G, Damschroder M, Herbst R, Hollingsworth RE, Sachsenmeier KF.

Oncoimmunology. 2016 Jul 11;5(8):e1208875. doi: 10.1080/2162402X.2016.1208875. eCollection 2016 Aug.


BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.

Shan W, Balog A, Quesnelle C, Gill P, Han WC, Norris D, Mandal S, Thiruvenkadam R, Gona KB, Thiyagarajan K, Kandula S, McGlinchey K, Menard K, Wen ML, Rose A, White R, Guarino V, Shen DR, Cvijic ME, Ranasinghe A, Dai J, Zhang Y, Wu DR, Mathur A, Rampulla R, Trainor G, Hunt JT, Vite GD, Westhouse R, Lee FY, Gavai AV.

Bioorg Med Chem Lett. 2015 May 1;25(9):1905-9. doi: 10.1016/j.bmcl.2015.03.038. Epub 2015 Mar 23.


Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.

Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.

Cancer Chemother Pharmacol. 2009 Jan;63(2):201-12. doi: 10.1007/s00280-008-0727-5. Epub 2008 Mar 19.


Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.

Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1065-74. doi: 10.1007/s00280-008-0699-5. Epub 2008 Feb 27.


Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.

Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, Flefleh C, Castaneda S, Inigo I, Kan D, Wen ML, Kramer R, Blackwood-Chirchir A, Lee FY.

Clin Cancer Res. 2006 Dec 1;12(23):7180-6.


Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.

Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Luo FR, Camuso A, McGlinchey K, Rose WC.

Mol Cancer Ther. 2006 Jan;5(1):104-13.


Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.

Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Wong TW, Kramer RA, Wild R, Lee FY.

Clin Cancer Res. 2005 Aug 1;11(15):5558-65.


Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.

Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY.

Cancer Chemother Pharmacol. 2005 Nov;56(5):455-64. Epub 2005 Jun 10.


Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.

Lombardo LJ, Camuso A, Clark J, Fager K, Gullo-Brown J, Hunt JT, Inigo I, Kan D, Koplowitz B, Lee F, McGlinchey K, Qian L, Ricca C, Rovnyak G, Traeger S, Tokarski J, Williams DK, Wu LI, Zhao Y, Manne V, Bhide RS.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1895-9.


Supplemental Content

Loading ...
Support Center